Alloplex Biotherapeutics
PrivateLast Round
Series A
Feb 9, 2023
Total Funding Raised
$21.7M
Company Overview
Alloplex Biotherapeutics, Inc. is a privately held, clinical-stage biotechnology company founded in 2016 with headquarters in Woburn, Massachusetts. The company focuses on developing cellular therapies for cancer treatment. Its proprietary ENLIST platform is used to create SUPLEXA, a non-engineered, autologous cellular therapy derived from a patient's own peripheral blood mononuclear cells. This therapy involves activating the patient's immune cells in a lab to enhance their natural cancer-fighting abilities before reintroducing them to the patient. Alloplex has completed a Phase I clinical trial in Australia, which demonstrated a strong safety profile and clinical activity in patients with solid tumors, including complete and partial responses in end-stage colorectal cancer patients. The company is planning to submit an Investigational New Drug (IND) application to the FDA and initiate Phase II trials in 2025, exploring SUPLEXA in combination with immune checkpoint inhibitors. Alloplex is actively seeking strategic partnerships and further investment to advance its clinical programs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alloplex Biotherapeutics Comps
Public and private peers based on sector, stage, and business model.
Alloplex Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 9, 2023 | ||||
| Seed | Aug 19, 2021 |
Alloplex Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Wells Investment | Series A |
| Keiretsu Forum | Series A |
Alloplex Biotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Alloplex Biotherapeutics's valuation, stock price, and market status.
